US demand for biotechnology pharmaceuticals will increase 13 percent annually to $15.9 billion in 2002.
Demand for biotechnology blood-related agents, the largest segment, will expand ten percent annually to $5.5 billion in 2002. An increasing base of dialysis, cancer, AIDS and transplant patients vulnerable to anemia and neutropenia will keep overall sales advancing favorably. New improved products, especially stem cell factor (SCF) and novel erythropoietin-stimulating protein (NESP), will add the strongest momentum to growth and partially offset the effect of tighter Medicare price controls over the use of epoetin alfa in dialysis.
Improvements in the dosing convenience and efficacy of combination AIDS therapies will push the demand for biotechnology antiviral agents up 14 percent annually to 2002. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors will see the fastest growth based on recommended HIV treatment guidelines. Fomivirsen sodium for AIDS-related CMV (cytomegalovirus) retinitis and palivizumab for RSV (respiratory syncytial virus) complications will increase the fastest in demand among other new products. New high value-added insulin delivery systems, magnified by the increasing market penetration of recombinant wound healing agents and fertility hormones, will boost the demand for biotechnology hormones and related agents over ten percent annually. Saturating patient bases for human growth hormones and recombinant imiglucerase will preclude faster growth.
Demand for biotechnology cardiovascular and related agents will increase rapidly, led by new therapies for congestive heart failure, heparin-induced thrombocytopenia and thrombolytic surgical complications Direct thrombin inhibitors will exhibit the fastest growth based on expanding indications in surgery and emergency care. New human monoclonal antibodies for breast cancer and non-Hodgkin's lymphoma will attain the highest sales levels among biotechnology antineoplastic agents due to improvements over conventional therapies and the size of the potential patient base.
Biotechnology in Pharmaceuticals (published 1/99, 267 pages) is available for $3400 from The Freedonia Group, Inc., 767 Beta Drive, Cleveland, OH 44143-2326. For further details, please contact Corinne Gangloff by phone 440.684.9600, fax 440.646.0484 or e-mail email@example.com. Full text is also available online through commercial database companies and the www.freedoniagroup.com Web site.
Please attribute information from this news release to The Freedonia Group (Cleveland, OH) and include, if possible, the price of the report. We would also appreciate a copy of the article or publication in which we appear.
|Printer friendly Cite/link Email Feedback|
|Comment:||US demand for biotechnology pharmaceuticals will increase 13 percent annually to $15.9 billion in 2002.|
|Publication:||Research Studies - Freedonia Group|
|Date:||Jan 1, 1999|
|Previous Article:||US demand for commercial refrigeration equipment is projected to increase over 5 percent annually through 2002 to $6.5 billion.|
|Next Article:||Worldwide sales of electric vehicles will increase 60 percent annually from a very low base to more than one million vehicles in the year 2007,...|